Cipher Pharmaceuticals
TSX:CPH Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
WA
Consensus Narrative from 3 Analysts
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Key Takeaways Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals. Expanding Natroba's market presence, out-licensing, and a diverse product portfolio are central to Cipher's growth strategy and improving net margins.
View narrativeCA$16.70
FV
25.1% undervalued intrinsic discount28.49%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
New narrative